Wave Life Sciences Business Summary

Wave Life Sciences Ltd. (WVE) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaboration agreements, utilizing a model built on upfront payments, research funding, and milestone-based incentives rather than commercial product sales. The company’s primary business segments are organized around its proprietary PRISM platform, which develops RNA-targeting therapeutics across four modalities: RNA editing (AIMers), siRNA (silencing), splicing, and antisense oligonucleotides. As of February 2026, Wave has pivoted toward high-growth metabolic indications, specifically targeting obesity with its INHBE-targeting siRNA (WVE-007) and liver diseases like AATD (WVE-006) and PNPLA3 (WVE-008). In the competitive landscape, Wave contends with Beam Therapeutics, Arrowhead Pharmaceuticals, and Korro Bio; it distinguishes itself as a pioneer in the RNA editing space, having achieved the first-ever clinical proof-of-mechanism for RNA editing in humans. The company was founded in 2012 by Dr. Gregory L. Verdine, a renowned Harvard professor and venture partner, and Dr. Takeshi Wada of the Tokyo University of Science. The leadership team is currently headed by President and CEO Paul Bolno, MD, MBA, who has overseen the company’s transition into a multi-platform RNA powerhouse, and Chief Technology Officer Chandra Vargeese, PhD, an expert in oligonucleotide chemistry with a pedigree from Merck and Sirna Therapeutics. Other key executives include Chief Scientific Officer Erik Ingelsson, MD, PhD, and CFO Kyle Moran. Wave is backed by a sophisticated group of institutional investors and strategic partners, including RA Capital Management, GSK (which remains a significant shareholder despite recently returning rights to the AATD program), and Fidelity Investments (FMR LLC), providing the firm with a robust cash runway extending into late 2028.